These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 11182745)

  • 61. Correlation of orbital computed tomography and antibodies in patients with hyperthyroid Graves' disease.
    Chang TC; Huang KM; Chang TJ; Lin SL
    Clin Endocrinol (Oxf); 1990 May; 32(5):551-8. PubMed ID: 2194711
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission.
    Eckstein AK; Lax H; Lösch C; Glowacka D; Plicht M; Mann K; Esser J; Morgenthaler NG
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):607-12. PubMed ID: 17880407
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Role of the underlying thyroid disease on the phenotype of Graves' orbitopathy in a tertiary referral center.
    Leo M; Menconi F; Rocchi R; Latrofa F; Sisti E; Profilo MA; Mazzi B; Albano E; Nardi M; Vitti P; Marcocci C; Marinò M
    Thyroid; 2015 Mar; 25(3):347-51. PubMed ID: 25584927
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Relationship of thyroid states and serum thrombomodulin (TM) levels in patients with Graves' disease: TM, a possible new marker of the peripheral activity of thyroid hormones.
    Morikawa Y; Morikawa A; Makino I
    J Clin Endocrinol Metab; 1993 Mar; 76(3):609-14. PubMed ID: 7680353
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Indium-111 octreotide in Graves' disease and in the evaluation of active exophthalmos.
    Mansi L; Rambaldi PF; Bizzarro A; Panza N; Di Martino S; De Bellis A; Del Vecchio E
    Q J Nucl Med; 1995 Jun; 39(2):105-10. PubMed ID: 8574802
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
    Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
    J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Natural History of Subclinical Hyperthyroidism in Graves' Disease: The Rule of Thirds.
    Zhyzhneuskaya S; Addison C; Tsatlidis V; Weaver JU; Razvi S
    Thyroid; 2016 Jun; 26(6):765-9. PubMed ID: 27090092
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prevalence and significance of antibodies reactive with eye muscle membrane antigens in sera from patients with Graves' ophthalmopathy and other thyroid and nonthyroid diseases.
    Wu YJ; Clarke EM; Shepherd P
    Thyroid; 1998 Feb; 8(2):167-74. PubMed ID: 9510126
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Strategies of radioiodine therapy for Graves' disease.
    Lind P
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S453-7. PubMed ID: 12192545
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
    Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
    J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Low response of the thyroid gland to endogenous thyrotropin increased by thyrotropin-releasing hormone in patients with euthyroid Graves' disease.
    Kashiwai T; Tada H; Watanabe Y; Shimaoka Y; Yagoro A; Hidaka Y; Fujikado T; Amino N
    Thyroid; 1998 Oct; 8(10):881-5. PubMed ID: 9827654
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
    Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R
    Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Oxidative Stress and Upregulation of Antioxidant Proteins, Including Adiponectin, in Extraocular Muscular Cells, Orbital Adipocytes, and Thyrocytes in Graves' Disease Associated with Orbitopathy.
    Marique L; Senou M; Craps J; Delaigle A; Van Regemorter E; Wérion A; Van Regemorter V; Mourad M; Nyssen-Behets C; Lengelé B; Baldeschi L; Boschi A; Brichard S; Daumerie C; Many MC
    Thyroid; 2015 Sep; 25(9):1033-42. PubMed ID: 26176182
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evidence for the effect of antibodies to TSH receptors on the thyroid ultrasonographic volume in patients with Graves' disease.
    Rieu M; Raynaud A; Richard A; Laplanche S; Sambor B; Berrod JL
    Clin Endocrinol (Oxf); 1994 Nov; 41(5):667-71. PubMed ID: 7828357
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Recombinant thyrotropin-induced orbital uptake of [111In-diethylenetriamine-pentacetic acid-D-Phe1]octreotide in a patient with inactive Graves' ophthalmopathy.
    Savastano S; Pivonello R; Acampa W; Salvatore M; Lombardi G; Colao A; Fenzi G
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2440-4. PubMed ID: 15687327
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy.
    Kung AW; Michon J; Tai KS; Chan FL
    Thyroid; 1996 Oct; 6(5):381-4. PubMed ID: 8936659
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves' opthalmopathy.
    Sawicka-Gutaj N; Budny B; Zybek-Kocik A; Sowiński J; Ziemnicka K; Waligórska-Stachura J; Ruchała M
    Endocrine; 2016 Aug; 53(2):497-504. PubMed ID: 26767650
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy.
    Colao A; Lastoria S; Ferone D; Pivonello R; Macchia PE; Vassallo P; Bonavolonta G; Muto P; Lombardi G; Fenzi G
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3790-4. PubMed ID: 9814448
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Increased percentage of L-selectin+ and ICAM-1+ peripheral blood CD4+/CD8+ T cells in active Graves' ophthalmopathy.
    Pawlowski P; Mysliwiec J; Stasiak-Barmuta A; Bakunowicz-Lazarczyk A; Gorska M
    Folia Histochem Cytobiol; 2009; 47(1):29-33. PubMed ID: 19419934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.